Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by SVB Leerink

SVB Leerink assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $5.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. StockNews.com raised Lexicon Pharmaceuticals to a sell rating in a research note on Monday, April 15th. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 23rd.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock opened at $1.74 on Tuesday. The stock’s fifty day simple moving average is $2.12 and its 200 day simple moving average is $1.74. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. The firm has a market cap of $428.46 million, a price-to-earnings ratio of -2.17 and a beta of 1.38. Lexicon Pharmaceuticals has a one year low of $0.92 and a one year high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. On average, analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of LXRX. Cantor Fitzgerald L. P. acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at $25,000. TIAA Trust National Association acquired a new position in shares of Lexicon Pharmaceuticals during the third quarter valued at $29,000. Principal Securities Inc. acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at $33,000. Commonwealth Equity Services LLC lifted its stake in shares of Lexicon Pharmaceuticals by 160.9% during the third quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 24,400 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Lexicon Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 22,043 shares during the period. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.